{
    "clinical_study": {
        "@rank": "24879", 
        "arm_group": [
            {
                "arm_group_label": "Delayed-release metformin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Extended-release metformin", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate how a single dose delayed-release metformin behaves in subjects\n      with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction, and\n      severe kidney dysfunction. The safety and tolerability of delayed-release metformin will\n      also be examined.\n\n      In addition, this study will compare the behavior of a single dose of delayed-release\n      metformin with that of extended-release metformin and placebo in subjects with the varying\n      levels of kidney function described above."
        }, 
        "brief_title": "Study Assessing the Behavior of Delayed-Release Metformin in Subjects With Kidney Dysfunction", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Insufficiency", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Is 18 to 80 (inclusive) years old at Visit 1 (Screening).\n\n          2. Is male, or is female and meets all of the following criteria:\n\n               -  Not breastfeeding\n\n               -  Negative pregnancy test result (human chorionic gonadotropin, beta subunit) at\n                  Visit 1 (Screening) (not applicable to hysterectomized females)\n\n               -  Surgically sterile, postmenopausal, or if of childbearing potential, must\n                  practice and be willing to continue to practice appropriate birth control during\n                  the entire duration of the study\n\n               -  Has body weight of \u2265 45 kg\n\n          3. Has a BMI of 18.0 to 40.0 kg/m2 (inclusive) at Visit 1 (Screening).\n\n          4. Has type 2 diabetes mellitus and an HbA1c \u226410.0%.\n\n          5. Has a physical examination with no clinically significant abnormalities as judged by\n             the investigator.\n\n          6. Has eGFR \u226515 mL/min/1.73 m2 based on the MDRD equation.\n\n          7. Ability to understand and willingness to adhere to protocol requirements\n\n        Exclusion Criteria:\n\n          1. Has End Stage Renal Disease requiring dialysis or severe renal dysfunction with eGFR\n             <15 mL/min/1.73 m2.\n\n          2. Is currently on dialysis or has been on dialysis within 12 months of Visit 1\n             (Screening).\n\n          3. Has received or plans to receive any iodinated contrast dye within 1 week prior to\n             Visit 1 (Screening) or after study medication administration.\n\n          4. Is currently taking or has taken within 1 week of Visit 1 cationic drugs that are\n             eliminated by renal tubular secretion (e.g., amiloride, digoxin, morphine,\n             procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and\n             vancomycin).\n\n          5. Has a clinically significant medical condition that could potentially affect study\n             participation and/or personal well-being, as judged by the investigator, including\n             but not limited to the following conditions:\n\n               -  Hepatic disease\n\n               -  Gastrointestinal disease\n\n               -  Endocrine disorder (type 2 diabetes mellitus is allowed)\n\n               -  Cardiovascular disease\n\n               -  Central nervous system diseases\n\n               -  Psychiatric or neurological disorders\n\n               -  Organ transplantation\n\n               -  Chronic or acute infection\n\n               -  Orthostatic hypotension, fainting spells or blackouts\n\n               -  Allergy or hypersensitivity\n\n          6. Has any chronic disease requiring medication that has been adjusted in the past 14\n             days(subjects may take acute intermittent over-the-counter medications such as\n             Tylenol, if needed).\n\n          7. Has had major surgery of any kind within 6 months of Visit 1 (Screening).\n\n          8. Has a clinically significant finding of an electrocardiogram (ECG) as assessed by the\n             investigator at Visit 1 (Screening).\n\n          9. Has clinical laboratory test (clinical chemistry, hematology, or urinalysis)\n             abnormalities, other than those related to diabetes or renal disease and other stable\n             diseases, judged by the investigator to be clinically significant at Visit 1\n             (Screening).\n\n         10. Has a hemoglobin result <8 g/dL or a level indicating severe anemia of renal origin.\n\n         11. Has physical, psychological, or historical finding that, in the investigator's\n             opinion, would make the subject unsuitable for the study.\n\n         12. Has received Byetta\u00ae or short-acting insulin within 3 days of Visit 1 (Screening).\n\n         13. Has received metformin within 4 weeks of Visit 1 (Screening).\n\n         14. Has any drug treatment that affects gastric pH (prescription or over-the-counter),\n             including any antacids or medications such as Rolaids or Pepcid within 2 days of\n             Visit 2.\n\n         15. Currently abuses drugs or alcohol or has a history of abuse that in the\n             investigator's opinion would cause the individual to be noncompliant with study\n             procedures.\n\n         16. Smokes more than 10 cigarettes, 3 cigars, or 3 pipes per day.\n\n         17. Has donated blood within 2 months of Visit 1 (Screening) or is planning to donate\n             blood during the study.\n\n         18. Has received any investigational drug within one month (or seven half-lives of the\n             investigational drug, whichever is greater) of Visit 1 (Screening).\n\n         19. Has known allergies or hypersensitivity to any component of study treatment.\n\n         20. Is employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract\n             worker, or designee of the company)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658514", 
            "org_study_id": "LCRM101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Delayed-release metformin", 
                "description": "Comparison of enteric-coating to assess effect on PK", 
                "intervention_name": "Delayed-release metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Extended-release metformin", 
                "description": "Active comparator", 
                "intervention_name": "Delayed-release metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014"
                    }, 
                    "name": "Clinical Pharmacology of Miami"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Compass Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Port Orange", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32127"
                    }, 
                    "name": "Prgressive Medical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40213"
                    }, 
                    "name": "Louisville Metabolic and Atherosclerosis Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Paul", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55114"
                    }, 
                    "name": "Prism Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Crossover Study Assessing the Single Dose Pharmacokinetics of Delayed-Release Metformin in Subjects With Renal Dysfunction", 
        "overall_official": [
            {
                "affiliation": "Prism Research", 
                "last_name": "George Canas, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Clinical Pharmacology of Miami", 
                "last_name": "Kenneth Lasseter, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Progressive Medical Research", 
                "last_name": "Alexander White, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Louisville Metabolic and Atherosclerosis Research Center", 
                "last_name": "Harold Bays, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Compass Research", 
                "last_name": "Craig Curtis, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Single dose AUC of delayed-release metformin in subjects with renal impairment Single dose Cmax of delayed-release metformin in subjects with renal impairment", 
                "measure": "Pharmacokinetics of delayed-release metformin", 
                "safety_issue": "No", 
                "time_frame": "PK will be assessed over 3 days following a single dose; washout of 2 to 5 days until next administration"
            }, 
            {
                "measure": "Characterize single dose exposure-response relationship of metformin and plasma lactate concentrations", 
                "safety_issue": "Yes", 
                "time_frame": "Plasma lactate measures over 3 days following single dose administration; 2-5 days washout until next dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658514"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Elcelyx Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Elcelyx Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}